Sleep and Anxiety Treatments from UK Doctors

Sleep and anxiety disorders are closely intertwined — 70-80% of patients with generalised anxiety disorder report insomnia, and chronic sleep deprivation itself generates anxiety through hyperactivation of the amygdala.

Understanding both conditions enables an integrated management approach.

Insomnia is defined as difficulty initiating sleep (sleep onset latency over 30 minutes), maintaining sleep (wakefulness after sleep onset over 30 minutes), or early morning awakening, occurring at least 3 nights per week for 3 months (chronic insomnia).

It affects 10% of adults to clinical diagnostic thresholds and 30% to symptomatic levels.

The Spielman 3P model explains insomnia chronicity:

• Predisposing factors: genetic tendency to hyperarousal, anxious temperament
• Precipitating events: life stressor, illness, pain, shift work change
• Perpetuating behaviours: excessive time in bed, daytime napping, clock-watching, caffeine use, phone screens in bed

Generalised anxiety disorder (GAD) involves persistent, excessive worry about multiple domains (health, finances, relationships, work) lasting at least 6 months, with associated physical symptoms — muscle tension, fatigue, irritability, poor concentration, and sleep disturbance.

UK prevalence is 5-6% over a lifetime, with women affected twice as often as men.

Other anxiety disorders encountered in primary care include:

• Panic disorder: recurrent unexpected panic attacks with anticipatory anxiety
• Social anxiety disorder: marked fear of social or performance situations
• Health anxiety: persistent preoccupation with having or acquiring a serious illness
• PTSD: following exposure to traumatic events, with intrusive memories, avoidance, and hyperarousal

Red flags in sleep and anxiety presentations requiring urgent assessment:

• Suicidal ideation or self-harm
• Psychotic features (paranoia, hallucinations)
• Severe functional impairment (unable to work, self-care, or leave the house)
• Suspected obstructive sleep apnoea (loud snoring, witnessed apnoeas, excessive daytime sleepiness, BMI over 35)

Medication plays a specific, time-limited role in sleep and anxiety management.

NICE guidelines emphasise that pharmacotherapy should complement, not replace, psychological and behavioural interventions.

Short-term hypnotics for acute insomnia:

• Zopiclone 7.5 mg (3.75 mg in elderly) is the most commonly prescribed Z-drug. It enhances GABA-A receptor activity, reducing sleep onset latency by 15-20 minutes and increasing total sleep time by 30-45 minutes. Onset is 15-30 minutes; half-life 5 hours. Common side effects include metallic taste (30%), dry mouth, and next-day drowsiness. Tolerance to the hypnotic effect develops within 14 days.
• NICE CG191 restricts hypnotic prescriptions to the lowest effective dose for the shortest period (maximum 2-4 weeks), with intermittent rather than nightly use preferred (e.g., 3-4 nights per week).

Benzodiazepines (temazepam, diazepam, nitrazepam) are second-line options.

They produce similar GABA enhancement but carry greater dependence liability, longer hangover effects, and higher risk of falls in elderly patients.

Diazepam's half-life of 20-100 hours (including active metabolites) makes it particularly inappropriate for nightly use.

SSRIs for anxiety disorders:

• Sertraline 50-200 mg daily is NICE first-line for GAD, panic disorder, social anxiety, and PTSD (CG113, CG159). Onset of anxiolytic effect takes 2-6 weeks. Initial worsening of anxiety in the first 1-2 weeks is common and can be managed by starting at 25 mg for 7 days.
• Escitalopram 10-20 mg and paroxetine 20-50 mg are alternatives when sertraline is not tolerated.

SNRIs: Venlafaxine 75-225 mg and duloxetine 60-120 mg are second-line for GAD when SSRIs fail. Venlafaxine carries a dose-dependent blood pressure elevation requiring monitoring.

Pregabalin 150-600 mg daily is licensed for GAD and provides anxiolysis within 1 week — faster than SSRIs.

However, NICE removed it as a first-line recommendation due to emerging dependence and misuse data. The MHRA reclassified pregabalin as Schedule 3 controlled drug in 2019.

Melatonin prolonged-release 2 mg (Circadin) is licensed for insomnia in adults over 55 for up to 13 weeks.

Evidence shows modest benefit (sleep onset latency reduced by 9-12 minutes) with minimal adverse effects and no dependence risk.

Cognitive behavioural therapy is the most effective long-term treatment for both chronic insomnia and anxiety disorders.

NICE recommends CBT as first-line — ahead of medication — because it produces sustained improvement without the dependence, tolerance, and withdrawal risks of pharmacotherapy.

CBT for insomnia (CBT-i) is a structured 4-8 session programme targeting the cognitive and behavioural factors that perpetuate insomnia. Components include:

Sleep restriction therapy: Limiting time in bed to match actual sleep time (e.g., 6 hours in bed for someone sleeping 5.

5 hours) consolidates sleep drive and eliminates the prolonged wakefulness in bed that conditions the brain to associate the bed with arousal.

Time in bed is gradually extended as sleep efficiency (sleep time / time in bed) exceeds 85%.

Stimulus control: Instructions to use the bed only for sleep and sex; leave the bedroom if unable to sleep within 15-20 minutes; return only when sleepy; maintain consistent wake time regardless of sleep quality.

This breaks the conditioned arousal response.

Cognitive restructuring: Identifying and challenging catastrophic thoughts about sleep ("If I don't sleep tonight, I won't function tomorrow") that amplify hyperarousal.

Replacing with realistic appraisals ("One poor night reduces performance by 5-10%, not 100%").

Relaxation training: Progressive muscle relaxation, diaphragmatic breathing, and body scan techniques reduce physiological hyperarousal at bedtime.

Efficacy data for CBT-i is compelling.

A meta-analysis of 20 RCTs showed that CBT-i reduces sleep onset latency by 19 minutes and wakefulness after sleep onset by 26 minutes — effects that are maintained at 12-month follow-up, unlike medication where effects cease on discontinuation.

The number needed to treat is 2.7 for clinically significant improvement.

CBT for anxiety targets the cognitive distortions (catastrophising, probability overestimation, intolerance of uncertainty) and avoidance behaviours that maintain the anxiety cycle.

NICE recommends 12-16 sessions of high-intensity CBT for GAD, delivered through NHS IAPT services or private therapists.

Digital CBT-i programmes (Sleepio, Sleepstation) are NICE-recommended and available on NHS prescription in many areas, providing an accessible alternative to face-to-face therapy.

Sleep hygiene refers to the environmental and behavioural conditions that promote consistent, restorative sleep.

While sleep hygiene alone is insufficient for chronic insomnia (it is a necessary but not sufficient component), combined with CBT-i and appropriate pharmacotherapy, it forms the foundation of long-term improvement.

Core sleep hygiene principles:

• Maintain consistent wake and sleep times 7 days per week — the circadian clock does not recognise weekends. Social jet lag (weekend lie-ins of 2+ hours) disrupts Monday-Tuesday sleep quality.
• Reserve the bedroom for sleep and intimacy only. Remove televisions, laptops, and work materials.
• Keep the bedroom dark (blackout blinds or an eye mask), quiet (earplugs or white noise machine), and cool (16-18 degrees Celsius is optimal for sleep onset).

Caffeine management: Caffeine's half-life is 5-6 hours, but individual CYP1A2 polymorphisms create slow metabolisers in whom caffeine persists 9-12 hours.

A pragmatic cut-off of 2:00 PM for the last caffeinated drink suits most people. Be aware of hidden caffeine in green tea (35 mg), dark chocolate (20-60 mg per 100 g), and pre-workout supplements.

Alcohol and sleep: Despite its sedative onset, alcohol fragments sleep architecture — it suppresses REM sleep in the first half of the night and causes rebound wakefulness in the second half.

More than 2 units within 4 hours of bedtime measurably worsens sleep quality.

Screen exposure: Blue light (460-480 nm wavelength) from phones, tablets, and laptops suppresses melatonin secretion by 50% when used within 2 hours of bedtime.

Night mode filters reduce but do not eliminate this effect. The content consumed (social media, news) also increases cognitive arousal.

Exercise timing: Regular exercise improves sleep quality (meta-analysis shows 13-minute reduction in sleep onset latency).

However, vigorous exercise within 2-3 hours of bedtime can raise core body temperature and cortisol, delaying sleep onset. Morning or afternoon exercise is optimal for sleep benefit.

Anxiety-specific lifestyle measures:

• Structured worry time (15-20 minutes in the early evening to write down concerns and action plans) prevents intrusive worry at bedtime
• Mindfulness meditation (10-20 minutes daily) reduces GAD symptom severity by 30-40% in controlled trials
• Regular physical activity is as effective as sertraline for mild-moderate anxiety in meta-analyses